ALX Oncology Holdings Inc.
ALXO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $116 | $142 | $98 | $60 |
| G&A Expenses | $26 | $28 | $29 | $23 |
| SG&A Expenses | $26 | $28 | $29 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $142 | $170 | $127 | $84 |
| Operating Income | -$142 | -$170 | -$127 | -$84 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8 | $9 | $4 | $0 |
| Pre-Tax Income | -$135 | -$161 | -$123 | -$83 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$135 | -$161 | -$123 | -$83 |
| % Margin | – | – | – | – |
| EPS | -2.58 | -3.74 | -3.03 | -2.07 |
| % Growth | 31% | -23.4% | -46.4% | – |
| EPS Diluted | -2.58 | -3.74 | -3.03 | -2.07 |
| Weighted Avg Shares Out | 52 | 43 | 41 | 40 |
| Weighted Avg Shares Out Dil | 52 | 43 | 41 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $11 | $4 | $0 |
| Interest Expense | $2 | $2 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$132 | -$158 | -$123 | -$83 |
| % Margin | – | – | – | – |